コンパニオン診断の世界市場レポート 2025年

コンパニオン診断の市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR21.5％で190億7,000万米ドルに成長します。予測期間の成長は、標的療法開発、感染症診断、希少疾患診断の増加、バイオマーカーに基づく医薬品開発の増加、ポイントオブケア検査、リキッドバイオプシー応用に起因すると考えられます。予測期間の主な動向には、免疫療法と免疫学の進歩、診断学におけるAIと機械学習、製品イノベーション、インダストリー4.0の採用、戦略的提携などが含まれます。

標的療法の増加はコンパニオン診断市場の成長を促進すると予想されます。標的療法とは、がん細胞の特定の特徴に焦点を当て、疾患の成長と拡大を遅らせる薬理学的アプローチを指します。これらの薬剤は全身を循環しますが、化学療法よりも正確な効果があり、副作用が少ないことが多いです。生物学的マーカーに基づくコンパニオン診断検査は、個別化がん治療の重要な要素になりつつあります。例えば、2024年2月、米国を拠点とする病院・ヘルスケア組織である個別化医療連合（Personalised Medicine Coalition）は、FDAが希少疾患患者のための新たな個別化治療を2022年の6件に対し、2023年には16件承認したと報告しました。その結果、標的療法の増加がコンパニオン診断市場の成長に拍車をかけています。

コンパニオン診断市場の成長は、慢性疾患の有病率の上昇によってさらに促進されます。コンパニオン診断は慢性疾患や非感染性疾患（NCDs）において、治療計画の調整、疾患進行のモニタリング、薬剤耐性の予測に使用されることが多くなっています。世界保健機関（WHO）の報告によると、世界の死亡者数の74％（4,100万人）に相当する年間4,100万人がNCDによって引き起こされています。特に、心血管疾患、がん、慢性呼吸器疾患、糖尿病などの疾病がこの負担に大きく寄与しています。慢性疾患の罹患率の増加は、患者の予後を改善し、市場全体の成長に貢献する上で、コンパニオン診断が不可欠な役割を担っていることを強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のコンパニオン診断市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のコンパニオン診断市場の成長率分析
• 世界のコンパニオン診断市場の実績：規模と成長、2019～2024年
• 世界のコンパニオン診断市場の予測：規模と成長、2024～2029年、2034年
• 世界のコンパニオン診断総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のコンパニオン診断市場：製品とサービス別、実績と予測、2019～2024年、2024～2029年、2034年
• アッセイ、キット、試薬
• ソフトウェアとサービス
• 世界のコンパニオン診断市場：技術別、実績と予測、2019～2024年、2024～2029年、2034年
• ポリメラーゼ連鎖反応
• 次世代シーケンシング
• インサイチューハイブリダイゼーション
• 免疫組織化学
• 世界のコンパニオン診断市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 肺がん
• 乳がん
• 大腸がん
• 白血病
• 悪性黒色腫
• 世界のコンパニオン診断市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 製薬・バイオ医薬品企業
• リファレンスラボ
• 受託研究機関
• 世界のコンパニオン診断市場：アッセイのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ポリメラーゼ連鎖反応（PCR）アッセイ
• 免疫組織化学（IHC）アッセイ
• 次世代シーケンシング（NGS）アッセイ
• インサイチューハイブリダイゼーション（ISH）アッセイ
• 世界のコンパニオン診断市場：キットと試薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 診断キット
• 検出試薬
• コントロール試薬
• 世界のコンパニオン診断市場：ソフトウェアとサービスのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• データ分析ソフトウェア
• 解釈ソフトウェア
• カスタム開発サービス
• コンサルティングおよびサポートサービス

第7章 地域別・国別分析

• 世界のコンパニオン診断市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のコンパニオン診断市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• コンパニオン診断市場：競合情勢
• コンパニオン診断市場：企業プロファイル
  • F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Qiagen NV Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abnova Corp.
• Amoy Diagnostics Co. Ltd.
• ARUP Laboratories
• Bayer AG
• Biomerieux SA
• Danaher Corporation
• Guardant Health Inc.
• Illumina Inc.
• Myriad Genetics Inc.
• Siemens Healthcare GmbH
• Almac Group
• Caris Life Sciences
• Cepheid Inc.
• Diaceutics plc
• Epic Sciences Inc.

第32章 世界市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 市場の最近の動向

第35章 市場の潜在力が高い国、セグメント、戦略

• コンパニオン診断市場2029年-最も新しい機会を提供する国
• コンパニオン診断市場2029年-最も新しい機会を提供するセグメント
• コンパニオン診断市場2029年-成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Companion diagnostics refer to in vitro diagnostic medical tests employed to assess the safety and effectiveness of a corresponding drug or biological product. These tests play a crucial role in helping healthcare professionals match patients with specific drugs or therapies.

The primary products and services in the companion diagnostics market include assays, kits, reagents, software, and related services. Assays, kits, and reagents find applications in various life science, environmental, and research laboratories. Assays are procedures used to examine substances for composition or quality, kits are collections of equipment and materials for specific purposes, and reagents are chemicals used in laboratory testing. Technologies such as polymerase chain reaction, next-generation sequencing, in situ hybridization, and immunohistochemistry are employed in companion diagnostics. These diagnostic tools are instrumental in identifying various cancer diseases like lung, breast, colorectal, leukemia, and melanoma. The primary users of companion diagnostics include pharmaceutical and biopharmaceutical companies, reference laboratories, and contract research organizations.

The companion diagnostics market research report is one of a series of new reports from The Business Research Company that provides companion diagnostics market statistics, including companion diagnostics industry global market size, regional shares, competitors with a companion diagnostics market share, detailed companion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the companion diagnostics industry. This companion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The companion diagnostics market size has grown rapidly in recent years. It will grow from $7.34 billion in 2024 to $8.75 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to increased adoption of personalized medicine, growth of oncology and cancer therapies, increased pharmaceutical r&d collaboration, precision medicine initiatives, and biomarker discovery.

The companion diagnostics market size is expected to see exponential growth in the next few years. It will grow to $19.07 billion in 2029 at a compound annual growth rate (CAGR) of 21.5%. The growth in the forecast period can be attributed to targetedTherapy development, infectious disease diagnostics, increasing rare disease diagnostics, increasing biomarker-based drug development, point-of-care testing, and liquid biopsy applications. Major trends in the forecast period include immunotherapy and immunology advances, ai and machine learning in diagnostics, product innovations, adoption of industry 4.0, strategic collaborations.

The rising number of targeted therapies is anticipated to drive the growth of the companion diagnostics market. Targeted therapy refers to a pharmacological approach that focuses on specific characteristics of cancer cells to slow down the disease's growth and spread. While these medications circulate throughout the body, they have a more precise effect than chemotherapy and often result in fewer side effects. Companion diagnostic testing based on biological markers is becoming a crucial component of personalized cancer care. For example, in February 2024, the Personalised Medicine Coalition, a US-based hospital and healthcare organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, compared to six in 2022. Consequently, the increase in targeted therapies is fueling growth in the companion diagnostics market.

The growth of the companion diagnostics market is further propelled by the rising prevalence of chronic diseases. Companion diagnostics are increasingly used in chronic diseases or non-communicable diseases (NCDs) to tailor treatment plans, monitor disease progression, and predict drug resistance. The World Health Organization reported that 74% of global deaths, equivalent to 41 million, are caused by NCDs annually. Notably, diseases such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contribute significantly to this burden. The rising incidence of chronic diseases underscores the essential role of companion diagnostics in enhancing patient outcomes and contributing to the overall growth of the market.

A key trend in the companion diagnostics market is technological advancement, particularly the integration of artificial intelligence (AI). AI is being leveraged to develop more efficient drugs and advance companion diagnostics. The extensive genetic profiling data sets, continuously generated, enable the application of AI to identify insights into disease causes. For example, Toronto-based start-up Deep Genomics is utilizing AI to expedite the discovery of better medications for genetic illnesses. Through deep learning, scientists can explore the human genome, analyze billions of chemical compounds, and identify promising formulations for clinical trials. This application of AI in companion diagnostics aligns with the broader trend of technological innovation, driving advancements in the field.

Major players in the companion diagnostics market are joining forces to create innovative treatment solutions aimed at enhancing personalized medicine, improving patient outcomes, and optimizing the effectiveness of targeted therapies. This collaboration among companies will accelerate the development and commercialization of companion diagnostics (CDx) for hematology and oncology treatments. For instance, in January 2024, Agilent Technologies, Inc., a California-based company providing instruments, software, services, and consumables for laboratories, announced a partnership with Incyte, a US-based pharmaceutical company. This collaboration combines Agilent's expertise and established track record in developing companion diagnostics (CDx) to support Incyte's hematology and oncology portfolio. As a result, Agilent will expand its CDx portfolio with new biomarkers, while Incyte will leverage Agilent's proficiency in assay development, regulatory approvals, and commercialization to facilitate clinical trials and CDx registration in the U.S. and Europe.

In August 2022, Genome Diagnostics, a UK-based testing company that offers personalized health insights to assist with diagnosis, treatment, and drug discovery, acquired Eurobio Scientific for USD 148.22 million. This acquisition allows GenDx to broaden its global presence, strengthen customer support in transplant diagnostics, and sustain its R&D and educational initiatives. Eurobio Scientific is a France-based company specializing in the research, development, and marketing of diagnostic products and life-science research products.

Major companies operating in the companion diagnostics market include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Abnova Corp., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, Biomerieux SA, Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sividon Diagnostics GmbH, Sysmex Corporation, Ventana Medical Systems, Vermillion Inc.

North America was the largest region in the companion diagnostics market in 2024. The regions covered in the companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the companion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The companion diagnostics market includes revenues earned by theranostics and monitoring tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Companion Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on companion diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for companion diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The companion diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product And Service: Assays, Kits And Reagents; Software And Services
• 2) By Technology: Polymerase Chain Reaction; Next-Generation Sequencing; In Situ Hybridization; Immunohistochemistry
• 3) By Indication: Lung Cancer; Breast Cancer; Colorectal Cancer; Leukemia; Melanoma
• 4) By End-User: Pharmaceutical And Biopharmaceutical Companies; Reference Laboratories; Contract Research Organizations
• Subsegments:
• 1) By Assays: Polymerase Chain Reaction (PCR) Assays; Immunohistochemistry (IHC) Assays; Next-Generation Sequencing (NGS) Assays; In Situ Hybridization (ISH) Assays
• 2) By Kits And Reagents: Diagnostic Kits; Detection Reagents; Control Reagents
• 3) By Software And Services: Data Analysis Software; Interpretation Software; Custom Development Services; Consulting and Support Services
• Companies Mentioned: F Hoffmann-La Roche Ltd.; Agilent Technologies Inc.; Qiagen NV; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Companion Diagnostics Market Characteristics

3. Companion Diagnostics Market Trends And Strategies

4. Companion Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Companion Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Companion Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Companion Diagnostics Market Growth Rate Analysis
• 5.4. Global Companion Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Companion Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Companion Diagnostics Total Addressable Market (TAM)

6. Companion Diagnostics Market Segmentation

• 6.1. Global Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Assays, Kits And Reagents
• Software And Services
• 6.2. Global Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction
• Next-Generation Sequencing
• In Situ Hybridization
• Immunohistochemistry
• 6.3. Global Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Melanoma
• 6.4. Global Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical And Biopharmaceutical Companies
• Reference Laboratories
• Contract Research Organizations
• 6.5. Global Companion Diagnostics Market, Sub-Segmentation Of Assays, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction (PCR) Assays
• Immunohistochemistry (IHC) Assays
• Next-Generation Sequencing (NGS) Assays
• In Situ Hybridization (ISH) Assays
• 6.6. Global Companion Diagnostics Market, Sub-Segmentation Of Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostic Kits
• Detection Reagents
• Control Reagents
• 6.7. Global Companion Diagnostics Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Data Analysis Software
• Interpretation Software
• Custom Development Services
• Consulting and Support Services

7. Companion Diagnostics Market Regional And Country Analysis

• 7.1. Global Companion Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Companion Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Companion Diagnostics Market

• 8.1. Asia-Pacific Companion Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Companion Diagnostics Market

• 9.1. China Companion Diagnostics Market Overview
• 9.2. China Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Companion Diagnostics Market

• 10.1. India Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Companion Diagnostics Market

• 11.1. Japan Companion Diagnostics Market Overview
• 11.2. Japan Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Companion Diagnostics Market

• 12.1. Australia Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Companion Diagnostics Market

• 13.1. Indonesia Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Companion Diagnostics Market

• 14.1. South Korea Companion Diagnostics Market Overview
• 14.2. South Korea Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Companion Diagnostics Market

• 15.1. Western Europe Companion Diagnostics Market Overview
• 15.2. Western Europe Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Companion Diagnostics Market

• 16.1. UK Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Companion Diagnostics Market

• 17.1. Germany Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Companion Diagnostics Market

• 18.1. France Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Companion Diagnostics Market

• 19.1. Italy Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Companion Diagnostics Market

• 20.1. Spain Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Companion Diagnostics Market

• 21.1. Eastern Europe Companion Diagnostics Market Overview
• 21.2. Eastern Europe Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Companion Diagnostics Market

• 22.1. Russia Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Companion Diagnostics Market

• 23.1. North America Companion Diagnostics Market Overview
• 23.2. North America Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Companion Diagnostics Market

• 24.1. USA Companion Diagnostics Market Overview
• 24.2. USA Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Companion Diagnostics Market

• 25.1. Canada Companion Diagnostics Market Overview
• 25.2. Canada Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Companion Diagnostics Market

• 26.1. South America Companion Diagnostics Market Overview
• 26.2. South America Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Companion Diagnostics Market

• 27.1. Brazil Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Companion Diagnostics Market

• 28.1. Middle East Companion Diagnostics Market Overview
• 28.2. Middle East Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Companion Diagnostics Market

• 29.1. Africa Companion Diagnostics Market Overview
• 29.2. Africa Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Companion Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Companion Diagnostics Market Competitive Landscape
• 30.2. Companion Diagnostics Market Company Profiles
  • 30.2.1. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Qiagen NV Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Companion Diagnostics Market Other Major And Innovative Companies

• 31.1. Abnova Corp.
• 31.2. Amoy Diagnostics Co. Ltd.
• 31.3. ARUP Laboratories
• 31.4. Bayer AG
• 31.5. Biomerieux SA
• 31.6. Danaher Corporation
• 31.7. Guardant Health Inc.
• 31.8. Illumina Inc.
• 31.9. Myriad Genetics Inc.
• 31.10. Siemens Healthcare GmbH
• 31.11. Almac Group
• 31.12. Caris Life Sciences
• 31.13. Cepheid Inc.
• 31.14. Diaceutics plc
• 31.15. Epic Sciences Inc.

32. Global Companion Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Companion Diagnostics Market

34. Recent Developments In The Companion Diagnostics Market

35. Companion Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Companion Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Companion Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Companion Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer